Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2025)

Historic Total Liabilities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $18.4 million.

  • SAB Biotherapeutics' Total Liabilities rose 875.7% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 875.7%. This contributed to the annual value of $18.2 million for FY2024, which is 3158.91% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Total Liabilities stood at $18.4 million, which was up 875.7% from $18.1 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Total Liabilities peaked at $42.6 million during Q4 2021, and registered a low of $7.9 million during Q1 2021.
  • Its 5-year average for Total Liabilities is $18.8 million, with a median of $18.2 million in 2024.
  • Data for SAB Biotherapeutics' Total Liabilities shows a peak YoY increase of 24539.64% (in 2022) and a maximum YoY decrease of 5340.15% (in 2022) over the last 5 years.
  • Over the past 5 years, SAB Biotherapeutics' Total Liabilities (Quarter) stood at $42.6 million in 2021, then tumbled by 53.4% to $19.8 million in 2022, then soared by 34.24% to $26.6 million in 2023, then plummeted by 31.59% to $18.2 million in 2024, then grew by 0.81% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $18.1 million for Q2 2025, and $16.7 million during Q1 2025.